| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4921.0 | 4197.0 | 3178.0 |
| Other income | -12.0 | -17.0 | -37.0 |
| Total income | 4909.0 | 4180.0 | 3141.0 |
| Profit before exceptional items & tax | 754.0 | 595.0 | 738.0 |
| Exceptional items | 21.0 | 66.0 | 0.0 |
| Profit before tax | 733.0 | 529.0 | 738.0 |
| Net profit | 566.0 | 364.0 | 548.0 |
| Operating margin | 14.9% | 12.7% | 23.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +3.30% |
|---|---|
| Net profit, quarter on quarter | +55.50% |
| Revenue, year on year | +54.80% |
| Operating profit, year on year | -1.20% |
| Operating profit, quarter on quarter | +51.70% |
NSE results filing, NSE: TORNTPHARM. Figures extracted from the filing.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,716.20
- Market cap
- ₹1,79,389 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 82.2×Sector 47.4×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals Limited has been assigned an ESG rating of 70 by NSE Sustainability Ratings and Analytics Limited. This independent assessment follows SEBI's regulatory framework for ESG Rating Providers.
Torrent Pharmaceuticals Annual General Meeting
Torrent Pharmaceuticals issued a Postal Ballot notice to shareholders for the appointment of Shanti Ekambaram as an Independent Director. Voting concludes on September 6, 2026.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals submitted a statement under Regulation 52(7) & (7A) regarding the utilization of issue proceeds for the quarter ended June 30, 2026.
Torrent Pharmaceuticals Management Change
Torrent Pharmaceuticals appointed Shanti Ekambaram as an Additional Independent Director. The appointment is for a three-year term effective July 30, 2026.